109 4 Diabetes-tuberculosis comorbidity in a low-income setting 30. Rajaa S, Krishnamoorthy Y, Knudsen S, Roy G, Ellner J, Horsburgh CR, et al. Prevalence and factors associated with diabetes mellitus among tuberculosis patients in South India-a cross-sectional analytical study. BMJ Open. 2021 Oct 22;11(10):e050542. 31. Ozma MA, Rashedi J, Poor BM, Vegari A, Asgharzadeh V, Kafil HS, et al. Tuberculosis and Diabetes Mellitus in Northwest of Iran. Infect Disord Drug Targets. 2020;20(5):667–71. 32. Hoa NB, Phuc PD, Hien NT, Hoa VQ, Thuong PH, Anh PT, et al. Prevalence and associated factors of diabetes mellitus among tuberculosis patients in Hanoi, Vietnam. BMC Infect Dis. 2018 Nov 29;18(1):603. 33. Aftab H, Ambreen A, Jamil M, Garred P, Petersen JH, Nielsen SD, et al. High prevalence of diabetes and anthropometric heterogeneity among tuberculosis patients in Pakistan. Tropical Medicine & International Health [Internet]. 2017 [cited 2023 Aug 20];22(4):465–73. Available from: https:// onlinelibrary.wiley.com/doi/abs/10.1111/tmi.12842 34. Ade S, Affolabi D, Agodokpessi G, Wachinou P, Faïhun F, Toundoh N, et al. Low prevalence of diabetes mellitus in patients with tuberculosis in Cotonou, Benin. Public Health Action. 2015 Jun 21;5(2):147–9. 35. Beraldo AA, Andrade RL de P, Pinto ÉSG, da Silva-Sobrinho RA, Saita NM, Monroe AA, et al. Tuberculosis and diabetes mellitus: sociodemographic and clinical profile in Brazilian municipalities. Rev Gaucha Enferm. 2021;42:e2020247. 36. Raghuraman S, Vasudevan KP, Govindarajan S, Chinnakali P, Panigrahi KC. Prevalence of Diabetes Mellitus among Tuberculosis Patients in Urban Puducherry. N Am J Med Sci. 2014 Jan;6(1):30–4. 37. Alavi SM, Khoshkhoy MM. Pulmonary tuberculosis and diabetes mellitus: Co-existence of both diseases in patients admitted in a teaching hospital in the southwest of Iran. Caspian J Intern Med [Internet]. 2012 [cited 2023 Aug 20];3(2):421–4. Available from: https://www.ncbi.nlm.nih. gov/pmc/articles/PMC3861906/ 38. Munseri PJ, Kimambo H, Pallangyo K. Diabetes mellitus among patients attending TB clinics in Dar es Salaam: a descriptive cross-sectional study. BMC Infect Dis. 2019 Oct 29;19(1):915. 39. Kajogoo VD, Amogne W, Medhin G. New onset type 2 diabetes mellitus risks with integrase strand transfer inhibitors-based regimens: A systematic review and meta-analysis. Metabol Open. 2023 Mar;17:100235. 40. Namara D, Schwartz JI, Tusubira AK, McFarland W, Birungi C, Semitala FC, et al. The risk of hyperglycemia associated with use of dolutegravir among adults living with HIV in Kampala, Uganda: A case-control study. Int J STD AIDS. 2022 Dec;33(14):1158–64. 41. Duga AL, Magongo S, Nhlabatsi S, Ladwar DO, Härmark L, Rolfes L. An evaluation of postmarketing reports of hyperglycaemia associated with dolutegravir for treatment of HIV in Eswatini. AIDS Res Ther. 2022 Nov 24;19(1):54. 42. Gezahegn H, Ibrahim M, Mulat E. Diabetes Mellitus and Tuberculosis Comorbidity and Associated Factors Among Bale Zone Health Institutions, Southeast Ethiopia. DMSO [Internet]. 2020 Oct [cited 2023 Aug 20];Volume 13:3879–86. Available from: https://www.dovepress.com/diabetesmellitus-and-tuberculosis-comorbidity-and-associated-factors--peer-reviewed-article-DMSO 43. Omar N, Wong J, Thu K, Alikhan MF, Chaw L. Prevalence and associated factors of diabetes mellitus among tuberculosis patients in Brunei Darussalam: A 6-year retrospective cohort study. Int J Infect Dis. 2021 Apr;105:267–73. 44. Magee MJ, Salindri AD, Kyaw NTT, Auld SC, Haw JS, Umpierrez GE. Stress Hyperglycemia in Patients with Tuberculosis Disease: Epidemiology and Clinical Implications. Curr Diab Rep. 2018 Aug 9;18(9):71.
RkJQdWJsaXNoZXIy MTk4NDMw